Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cornerstone BioPharma Holdings, a specialty pharmaceutical company, has appointed David Price as its new executive vice president of finance and CFO.
Subscribe to our email newsletter
Mr Price will begin working at Cornerstone from September 8, 2008. He is currently serving as a managing director with Jefferies and leads its pharmaceutical services division. In this role, Mr Price has provided investment banking advice to various specialty pharmaceutical companies, including Cornerstone, and has been Jefferies’s lead representative in connection with Cornerstone’s proposed merger with Critical Therapeutics.
Announced in May 2008, Cornerstone’s merger with the publicly held Critical Therapeutics is targeted to close in the fourth quarter of 2008.
Craig Collard, president and CEO of Cornerstone, said: “In addition to traditional financial duties, Price will be invaluable in helping guide Cornerstone’s transition into a publicly traded company. We’re pleased to have David’s talent and efforts supporting our executive team as well as our new stockholders.”